The multifaceted effects of semaglutide
Semaglutide , a GLP-1 receptor agonist , is FDA-approved for managing type 2 diabetes (T2D) and reducing cardiovascular risk. Its off-label use in weight management and other conditions has grown, prompting a review of its benefits and risks. This ...
This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist , in the treatment of obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy in weight reduction, with superior results compared to other treatments in the same class. Its effects include appetite suppression, increased satiety, and improvements in ...
Oral GLP
Therapy for type 2 diabetes with GLP-1 receptor agonists initially necessitated subcutaneous injection of a peptide analogue of the incretin hormone GLP-1.1 Oral administration of a GLP-1 receptor agonist was first achieved when the peptide semaglutide was co-administered with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl]amino) caprylate.2 With some inconvenience (oral administration ...
The development of glucagon-like peptide 1 ( GLP1 ) receptor agonists , including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity.
A New GLP
An investigational oral glucagon-like peptide-1 ( GLP-1 ) receptor agonist for diabetes, an injection that combines semaglutide with an amylin analogue, data from China on high-dose mazdutide, and more were on the docket at the American Diabetes Association (ADA) annual flagship meeting, which took place recently in New Orleans.
In previous studies, a long-acting glucagon-like peptide-1 receptor agonist ( GLP-1 RA) semaglutide has been identified as one of the most promising medications for treating obesity.
New Weight Loss Drugs
The most commonly prescribed GLP-1 agonist is semaglutide , which has gained popularity in recent years after the Food and Drug Administration (FDA) approved it for the treatment of diabetes in 2017 (under the brand name Ozempic), for the treatment of obesity in 2021 (under the brand name Wegovy), and for reducing cardiovascular disease risk in ...
This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor ( GLP -1R) agonists , tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding ...
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Semaglutide , a glucagon-like peptide-1 receptor agonist , has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular ...
At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.